KORKMAZ, L. Et Al. 2022. Which Inotropic Drug, Dobutamine or Milrinone, Is Clinically More Effective in the Treatment of Postligation Cardiac Syndrome in Preterm Infants?. AMERICAN JOURNAL OF PERINATOLOGY , vol.39, no.2 , 204-215.

KORKMAZ, L., Ozdemir, A., PAMUKÇU, Ö., GÜNEŞ, T., & ÖZTÜRK, M. A., (2022). Which Inotropic Drug, Dobutamine or Milrinone, Is Clinically More Effective in the Treatment of Postligation Cardiac Syndrome in Preterm Infants?. AMERICAN JOURNAL OF PERINATOLOGY , vol.39, no.2, 204-215.

KORKMAZ, Levent Et Al. "Which Inotropic Drug, Dobutamine or Milrinone, Is Clinically More Effective in the Treatment of Postligation Cardiac Syndrome in Preterm Infants?," AMERICAN JOURNAL OF PERINATOLOGY , vol.39, no.2, 204-215, 2022

KORKMAZ, Levent Et Al. "Which Inotropic Drug, Dobutamine or Milrinone, Is Clinically More Effective in the Treatment of Postligation Cardiac Syndrome in Preterm Infants?." AMERICAN JOURNAL OF PERINATOLOGY , vol.39, no.2, pp.204-215, 2022

KORKMAZ, L. Et Al. (2022) . "Which Inotropic Drug, Dobutamine or Milrinone, Is Clinically More Effective in the Treatment of Postligation Cardiac Syndrome in Preterm Infants?." AMERICAN JOURNAL OF PERINATOLOGY , vol.39, no.2, pp.204-215.

@article{article, author={Levent KORKMAZ Et Al. }, title={Which Inotropic Drug, Dobutamine or Milrinone, Is Clinically More Effective in the Treatment of Postligation Cardiac Syndrome in Preterm Infants?}, journal={AMERICAN JOURNAL OF PERINATOLOGY}, year=2022, pages={204-215} }